GET THE APP
HER2 Testing | Open Access Journals
..

Journal of Oncology Medicine & Practice

ISSN: 2576-3857

Open Access
Spanish Chinese Russian German French Japanese Portuguese Hindi Telugu Tamil
Submit Manuscript arrow_forward arrow_forward ..

HER2 Testing

HER2-positive bosom diseases will in general be more forceful than different kinds of bosom malignant growth. Medicines that explicitly target HER2 are powerful. These medicines are successful to such an extent that the forecast for HER2-positive bosom disease is very acceptable. Certain standard chemotherapy tranquilizes likewise can be compelling in rewarding HER2-positive bosom tumors, in spite of the fact that these medications don't explicitly focus on the HER2 protein. Specialists suggest that each intrusive bosom malignancy be tried for the nearness of HER2 on the grounds that the outcomes fundamentally sway treatment proposals and choices. HER2 testing isn't done routinely for ductal carcinoma in situ, aside from as a ma jor aspect of a clinical preliminary.

High Impact List of Articles
Conference Proceedings

Relevant Topics in Medical Sciences

Awards & Nominations

50+ Million Readerbase

Journal Highlights

Google Scholar citation report
Citations: 142

Journal of Oncology Medicine & Practice received 142 citations as per Google Scholar report

Citation image
Journal of Oncology Medicine & Practice peer review process verified at publons
Publon image

Indexed In

Related Links

 

Open Access Journals

arrow_upward arrow_upward